Viatris Inc. and Pharming Group N.V.: A Detailed Gross Profit Analysis

Viatris vs. Pharming: A Decade of Gross Profit Growth

__timestampPharming Group N.V.Viatris Inc.
Wednesday, January 1, 2014215951653669400000
Thursday, January 1, 201565904274382200000
Friday, January 1, 2016117685424998500000
Sunday, January 1, 2017925870384976200000
Monday, January 1, 20181292038434572000000
Tuesday, January 1, 20191654124474444200000
Wednesday, January 1, 20202030564303796700000
Friday, January 1, 20211696700715575500000
Saturday, January 1, 20221880600006497000000
Sunday, January 1, 20232201040006438600000
Loading chart...

Unveiling the hidden dimensions of data

A Comparative Analysis of Gross Profit Trends: Viatris Inc. vs. Pharming Group N.V.

In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. This analysis delves into the gross profit trends of Viatris Inc. and Pharming Group N.V. from 2014 to 2023. Viatris Inc., a global healthcare giant, consistently outperformed Pharming Group N.V., a niche player, with gross profits peaking at approximately $6.5 billion in 2022, a 77% increase from 2014. In contrast, Pharming Group N.V. showed a remarkable growth trajectory, with gross profits surging by over 900% during the same period, reaching around $220 million in 2023. This stark contrast highlights the diverse strategies and market positions of these companies. While Viatris Inc. maintains a steady growth, Pharming Group N.V. demonstrates agility and rapid expansion, reflecting the dynamic nature of the pharmaceutical sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025